Clinical Trial Update: Role of Omega-DEK in Childhood Apraxia of Speech [Phase 2]

View source ↗

Summary

This is a Phase 2 clinical trial evaluating Omega-DEK for childhood apraxia of speech and related verbal apraxia conditions, currently not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autism Spectrum Disorder
• Childhood Apraxia of Speech
• Verbal Apraxia

Drugs mentioned

• Omega-DEK

Snippet

Sponsor: Claudia R. Morris | Conditions: Childhood Apraxia of Speech, Verbal Apraxia | Phase 2 | Status: NOT_YET_RECRUITING